渤健Biogen (BIIB) 2009年年度报告「NASDAQ」.pdf

《渤健Biogen (BIIB) 2009年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen (BIIB) 2009年年度报告「NASDAQ」.pdf（16页珍藏版）》请在三个皮匠报告上搜索。

1、 DiscoveryInto Care 2009 ANNUAL REPORT MILESTONES&ACHIEVEMENTS2009Revenues for 2009 totaled$4.4 billion,an increase of 7 percent over 2008.Biogen Idec also filed for European and Canadian regulatory approval of fampridine and advanced two programs into registrational trials.Because of its powerful e

2、fficacy in multiple sclerosis,TYSABRI(natalizumab)became the Companys third blockbuster product,exceeding$1 billion in sales globally.SECTOR/BiotechnologyCORE BUSINESS /Human Therapeuti csPRODUCTS /AVONEX,TYSABRI,RITUXANOn the cover:BARBARA SALES,TYSABRI patient(top left)ED PRIME,AVONEX patient(midd

3、le right)SUSAN HELMS,RITUXAN patient(bottom left)EPS($)FREE CASH FLOW($in millions)REVENUES($in millions)2,422.52,683.03,171.64,097.54.377.32005200620072008200920052006200720082009200520062007200820091.572.252.743.664.12571.1644.1734.71,286.4909.31Note:EPS numbers are diluted non-GAAP,which excludes

4、 the impact of purchase accounting,merger-related adjustments,stock option expense,other items and their related tax effects.Free cash flow is defined as net cash flows provided by operating activities less purchases of property,plant and equipment,as disclosed within our Form 10-K.Reconciliation of

5、 GAAP to non-GAAP diluted EPS and free cash flow amounts are on pages 12-13 of this annual report.WORLDWIDE OPERATIONSOur International business accounted for 35 percent of our 2009 total revenues,demonstrating our commitment to capturing the greatest value from our products world-wide.A global biot

6、echnology leader,Biogen Idec has operations in 29 countries and distributors in another 60 2009,we once again delivered solid financial and operational results and continued to position the Company to build long-term value for our shareholders.Most notably,TYSABRI(natalizumab)achieved“blockbuster”st